How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Imiquimod in dermatology: an overview. (Abstract)

Imiquimod in dermatology: an overview. Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. This allows its use for the treatment of a wide variety of benign and malignant skin conditions due to its potential antiviral, antitumor, and immunoregulatory effects. Currently, topical imiquimod is US Food and Drug Administration (FDA)-approved for the treatment (...) of anogenital warts, actinic keratosis, and superficial basal cell carcinomas. However, it has also shown a beneficial effect in the treatment of many other skin disorders. In this review, we describe existing evidence on the mechanism of action of topical imiquimod, its FDA-approved indications, off-label uses, and side effects. © 2016 The International Society of Dermatology.

2016 International Journal of Dermatology

182. Leptin-deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. (Abstract)

Leptin-deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Leptin is an adipocyte-derived cytokine secreted mostly by adipose tissue. Serum leptin levels are elevated in obese individuals and correlate positively with body mass index (BMI). Interestingly, serum leptin levels are also elevated in patients with psoriasis and correlate positively with disease severity. Psoriasis is associated (...) with obesity; patients with psoriasis have a higher incidence of obesity, and obese individuals have a higher risk of developing psoriasis. Additionally, obese patients with psoriasis experience a more severe degree of psoriasis. In this study, we hypothesised that leptin may link psoriasis and obesity and plays an aggravating role in psoriasis. To investigate leptin's role in psoriasis, we applied the widely accepted imiquimod (IMQ)-induced psoriasis-like skin inflammation mouse model on leptin-deficient

2016 Experimental Dermatology

183. Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management. Full Text available with Trip Pro

Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management. Vaginal intraepithelial neoplasia (VAIN) is associated with human papillomavirus (HPV) infection. The most common treatment modality is laser vaporisation, but recurrences are common. Imiquimod is an immune response modulator which is used for the treatment of external condylomas and other HPV-related genital neoplasias. The aim of the study was to evaluate the efficacy (...) and tolerability of vaginally administered imiquimod in comparison with laser vaporisation and expectant management of high-grade VAIN. This proof of principle pilot study was a prospective 16-week randomised trial. We enrolled 30 patients with histologically confirmed VAIN 2 or 3 into three study arms: vaginally administered imiquimod, laser vaporisation and expectant management. Follow-up colposcopy visits included high-risk human papillomavirus (hrHPV) testing, cytology and punch biopsies. At baseline 77

2016 International journal of cancer Controlled trial quality: uncertain

184. Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis. (Abstract)

Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis. Psoriasis is a common chronic skin condition characterized by excessive inflammation and aberrant epidermal proliferation. Flightless I (Flii) is an actin-remodelling protein that regulates these processes, suggesting a possible role in psoriasis.We sought to determine whether a benefit in psoriasiform dermatitis might occur after modulating Flii gene expression (...) or reducing its levels using neutralizing antibodies.Biopsies of psoriatic skin lesions from patients were assessed for Flii levels. Psoriasis-like lesions were induced in Flii heterozygous (Flii+/- ), wild-type (Flii+/+ ) and Flii transgenic (FliiTg/Tg ) mice using topical application of imiquimod. Additionally, psoriasis-induced wild-type mice were treated with topical application of Flii neutralizing antibodies and erythema, inflammation and histology were assessed.Flii was elevated in psoriatic

2016 British Journal of Dermatology

185. Pretreatment with topical glucocorticosteroids to enhance the anti-tumour efficacy of imiquimod: long-term follow-up in Bowen's disease. (Abstract)

Pretreatment with topical glucocorticosteroids to enhance the anti-tumour efficacy of imiquimod: long-term follow-up in Bowen's disease. 27542777 2018 07 02 2018 12 02 1365-2133 176 4 2017 04 The British journal of dermatology Br. J. Dermatol. Pretreatment with topical glucocorticosteroids to enhance the antitumour efficacy of imiquimod: long-term follow-up in Bowen disease. 1079-1082 10.1111/bjd.14996 Okazaki A A Department of Dermatology, Kyorin University School of Medicine, Mitaka, Tokyo (...) Glucocorticoids 0 Ointments ADN79D536H Clobetasol P1QW714R7M Imiquimod IM Administration, Cutaneous Aged Aminoquinolines administration & dosage Antineoplastic Agents administration & dosage Bowen's Disease drug therapy CD3 Complex metabolism CD4-Positive T-Lymphocytes drug effects CD8-Positive T-Lymphocytes drug effects Clobetasol administration & dosage Drug Administration Schedule Drug Therapy, Combination Follow-Up Studies Forkhead Transcription Factors metabolism Glucocorticoids administration & dosage

2016 British Journal of Dermatology

186. Fractional Laser-Assisted Topical Imiquimod 5% Cream Treatment for Recalcitrant Common Warts in Children: A Pilot Study. (Abstract)

Fractional Laser-Assisted Topical Imiquimod 5% Cream Treatment for Recalcitrant Common Warts in Children: A Pilot Study. Conventional treatments for warts like cryotherapy are limited by the pain during procedures, especially in pediatric patients. Imiquimod is a topical immune response modifier, but the thick stratum corneum of common warts prevents drug permeation through skin.To evaluate the efficacy and safety of fractional laser/topical 5% imiquimod cream for the treatment of warts (...) in children.Eleven pediatric patients with multiple recalcitrant common warts were included. Lesions were treated using an ablative fractional 2,940-nm Er:YAG laser at 1- or 2-week interval. After each laser treatment session, imiquimod 5% cream was self-applied once daily 5 days a week. Response and adverse effects were assessed 2 weekly until complete clearance or up to maximum of 48 weeks. Pain during fractional laser was assessed using a visual analogue scale (0-10).Eight of the 11 (72.7%) children

2016 Dermatologic Surgery

187. Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice. Full Text available with Trip Pro

Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice. Psoriasis is a chronic inflammatory immune disease with undefined pathogenesis. It is associated with T cells, and the IL-23/IL17 axis is believed to be crucial in the pathogenesis. The present treatments have side effects that influence the compliance of patients. Tea polyphenol is extracted from tea polyphenols, and its main active ingredient is Epigallocatechin-3-gallate (EGCG), which has (...) been shown to have antioxidant, anti-tumor, and anti-ultraviolet radiation effects. Here, we aim to report that EGCG can inhibit imiquimod (IMQ)-induced psoriasis-like inflammation.We used BALB/c mice, which were topically treated with IMQ for 6 consecutive days, as a psoriasis mouse model. Topical application of EGCG and treatment with EGCG were conducted in the experiments. Then observed the effects of the two methods on psoriasis-like mice dermatitis. Statistics are presented as the means

2016 BMC Complementary and Alternative Medicine

189. Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model. Full Text available with Trip Pro

Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model. Psoriasis is a high-incident T-cell-mediated autoimmune disease mainly affecting the skin. Interleukin (IL)-27 is a novel member of the IL-6/IL-12 cytokine family, which plays a versatile role in the differentiation and function of distinct T cell subsets. Previous studies uncovered that IL-27 promoted the onset of psoriasis through enhancing (...) levels of IL-27 and IL-27 receptor (IL-27R) mRNA in the skin tissue and peripheral blood mononuclear cells (PBMC) were assessed by quantitative polymerase chain reaction (PCR) analysis. To explore the function of IL-27 in vivo, we used imiquimod (IMQ)-induced psoriasis mouse model. We treated mice with IL-27 or its antagonist, evaluated disease severity and detected the cytokine secretion from splenic CD4+ T cells by flow cytometric analysis and the expression levels of IL-17 and IFN-γ in serum

2016 Journal of dermatological science

190. Dermoscopic Ulceration is a Predictor of Basal Cell Carcinoma Response to Imiquimod: A Retrospective Study. Full Text available with Trip Pro

Dermoscopic Ulceration is a Predictor of Basal Cell Carcinoma Response to Imiquimod: A Retrospective Study. 27230691 2017 01 26 2018 12 02 1651-2057 97 1 2017 01 04 Acta dermato-venereologica Acta Derm. Venereol. Dermoscopic Ulceration is a Predictor of Basal Cell Carcinoma Response to Imiquimod: A Retrospective Study. 117-119 10.2340/00015555-2464 Urech Marta M Department of Dermatology, Hospital Ramón y Cajal, ES-28049 Madrid, Spain. marta.urech@gmail.com. Kyrgidis Athanassios A Argenziano (...) Giuseppe G Reggiani Camilla C Moscarella Elvira E Longo Caterina C Alfano Roberto R Zalaudek Iris I Lallas Aimilios A eng Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Aminoquinolines therapeutic use Antineoplastic Agents therapeutic use Carcinoma, Basal Cell drug therapy pathology Dermoscopy Female Humans Imiquimod Male Retrospective Studies Skin Neoplasms drug therapy pathology 2016 5 28 6 0 2017 1 27 6 0 2016 5 28 6 0

2016 Acta Dermato-Venereologica

191. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial (Abstract)

Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial Superficial basal-cell carcinoma is most commonly treated with topical non-surgical treatments, such as photodynamic therapy or topical creams. Photodynamic therapy is considered the preferable treatment, although this has not been previously tested in a randomised control trial. We assessed the effectiveness (...) of photodynamic therapy compared with imiquimod or fluorouracil in patients with superficial basal-cell carcinoma.In this single blind, non-inferiority, randomised controlled multicentre trial, we enrolled patients with a histologically proven superficial basal-cell carcinoma at seven hospitals in the Netherlands. Patients were randomly assigned to receive treatment with methylaminolevulinate photodynamic therapy (MAL-PDT; two sessions with an interval of 1 week), imiquimod cream (once daily, five times

2013 EvidenceUpdates Controlled trial quality: predicted high

192. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia

More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia Mahto M, Nathan M, O'Mahony C CRD summary This review suggested that 5% imiquimod cream was reasonably well tolerated and may be an alternative treatment for vulvar, penile and anal intraepithelial (...) neoplasias; there was no evidence regarding comparisons with traditional treatments. The review may not be reliable due to the risk of missing data, limited analyses and reliance on poorer study designs. Authors' objectives To evaluate the effectiveness of 5% imiquimod cream for the treatment of vulvar, penile and anal intraepithelial neoplasias (VIN, PIN and AIN). Searching MEDLINE, EMBASE and The Cochrane Library were searched for English-language studies published between 1997 and May 2009. Search

2010 DARE.

193. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model

Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate (...) of imiquimod versus photodynamic therapy (PDT) for the treatment of solar or actinic keratosis of the face and scalp, in patients with four to nine lesions, who were unsuitable for cryosurgery, topical diclofenac, and topical fluorouracil. The author concluded that PDT was unlikely to be cost-effective compared with imiquimod and a head-to-head trial was needed. The methods were robust and transparently presented. The author’s conclusions appear to be valid. Type of economic evaluation Cost-utility

2010 NHS Economic Evaluation Database.

194. Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men. (Abstract)

Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men. We assess the safety and efficacy of imiquimod cream 3.75% and 2.5% in men with external genital warts (EGWs). Two multicenter, randomized, double-blind, placebo-controlled studies were conducted in a total of 447 (225 from study 1 and 222 from study 2) male patients (aged ≥12 years) with 2 to 30 EGWs and a total wart area of 150 mm2 or greater. Participants were randomized (2:2:1) to imiquimod cream 3.75 (...) , adverse events (AEs), and clinical laboratory tests. Study results indicated that new imiquimod formulations are beneficial in treating EGWs in men.

2015 Cutis Controlled trial quality: predicted high

195. 5 year recurrence rate of lentigo maligna after treatment with imiquimod. (Abstract)

5 year recurrence rate of lentigo maligna after treatment with imiquimod. The current recommended treatment for lentigo maligna (LM) is surgical resection, which can cause significant scarring. The reported recurrence rate after Mohs micrographic surgery is 0-6·25%. There is little published data on long-term outcome after imiquimod therapy. Several reports record progression to LM melanoma during treatment. Clinical assessment of clearance is difficult. Histological confirmation is preferred (...) but risks sampling error and missing areas of invasion. Confocal microscopy can be used to assess entire lesions.To assess the 5-year recurrence rate of LM after imiquimod treatment.Forty patients with LM were treated with imiquimod between 2002 and 2007. Their previous treatments included cryotherapy, incomplete surgical excision and radiotherapy. All applied imiquimod three times per week for 6 weeks; 25 (62·5%) experienced inflammation. The other 15 (37·5%) then applied imiquimod five times per week

2015 British Journal of Dermatology

196. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative. Full Text available with Trip Pro

Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative. Periocular basal cell carcinomas (pBCC) remain a treatment challenge. Our aim was to retrospectively evaluate the feasibility and efficacy of immunocryosurgery for the treatment of pBCC.Immunocryosurgery is given in 5-week cycles of daily imiquimod, with cryosurgery on day 14. Patients treated between 1/1/2008 and 31/12/2014 were included

2015 Dermatology

197. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial. (Abstract)

Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial. Pretreatment with topical imiquimod, a synthetic agonist of toll-like receptor 7, significantly improved the immunogenicity of influenza vaccination in elderly people. We aimed to clarify its effect in a younger age group.In this double-blind, randomised controlled trial, we (...) enrolled healthy volunteers aged 18-30 years in early 2014 to receive the 2013-14 northern-hemisphere winter trivalent influenza vaccine at the Queen Mary Hospital, (Hong Kong, China). Eligible participants were randomly assigned (1:1:1:1) to one of the four vaccination groups: the study group, topical imiquimod-cream followed by intradermal trivalent influenza vaccine (INF-Q-ID), or one of three control groups, topical aqueous-cream control followed by intradermal trivalent influenza vaccine (INF-C-ID

2015 The Lancet. Infectious diseases Controlled trial quality: predicted high

198. A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose. (Abstract)

A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose. 26615810 2017 03 22 2018 12 02 1365-2133 174 5 2016 May The British journal of dermatology Br. J. Dermatol. A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose. 1134-6 10.1111/bjd.14330 Greveling K K Department of Dermatology, Erasmus MC University (...) , the Netherlands. eng Letter 2016 02 11 England Br J Dermatol 0004041 0007-0963 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Aged Aminoquinolines therapeutic use Antineoplastic Agents therapeutic use Combined Modality Therapy Facial Neoplasms therapy Female Head and Neck Neoplasms therapy Humans Hutchinson's Melanotic Freckle therapy Imiquimod Laser Therapy methods Leg Male Neoplasm Recurrence, Local etiology Nose Neoplasms therapy Skin Neoplasms therapy Treatment Outcome 2015 12 1 6 0

2015 British Journal of Dermatology

199. Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group. (Abstract)

Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group. Canine visceral leishmaniasis (CVL) is not only an emerging veterinary concern but also a public health threat in endemic areas. The aim of this study was to assess the efficacy, immunogenicity and safety of two doses of aluminum hydroxide (alum) precipitated Leishmania major (Alum-ALM) mixed with BCG plus imiquimod against (...) CVL.A total of 560 ownership dogs were serologically tested and 234 healthy dogs with no clinical signs of CVL, no anti-Leishmania antibodies and negative leishmanin skin test were selected and double-blind randomly injected intradermally either with 0.1 ml Alum-ALM (200µg protein) mixed with BCG (2 × 10(6) CFUs) plus imiquimod (121 dogs) or with 0.1 ml of normal saline (113 dogs).The follow-up examinations showed that there was no side effect associated with the vaccination except one case. Strong

2015 Iranian journal of parasitology Controlled trial quality: uncertain

200. Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'. (Abstract)

Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'. 25581585 2015 05 19 2018 12 02 1365-2133 172 1 2015 Jan The British journal of dermatology Br. J. Dermatol. Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non

2015 The British journal of dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>